Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
55
TLSA Quote, Financials, Valuation and Earnings
Last price:
$1.52
Seasonality move
:
-21.71%
Day range:
$1.46 - $1.56
52-week range:
$0.63 - $2.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,803.69x
P/B ratio:
65.31x
Volume:
211.6K
Avg. volume:
355.8K
1-year change:
121.74%
Market cap:
$181.8M
Revenue:
--
EPS (TTM):
-$0.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.64% | $7.20 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.53 | $7.99 | $181.8M | -- | $0.00 | 0% | 2,803.69x |
|
APM
Aptorum Group Ltd.
|
$1.19 | -- | $8.5M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.68 | $9.52 | $447.1M | -- | $0.00 | 0% | 8.72x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.87 | $17.94 | $2.4M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.30 | $7.20 | $365.7M | -- | $0.00 | 0% | 718.19x |
|
NCNA
NuCana Plc
|
$3.34 | $104.00 | $13.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Tiziana Life Sciences Ltd. vs. Competitors
-
Which has Higher Returns TLSA or APM?
Aptorum Group Ltd. has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About TLSA or APM?
Tiziana Life Sciences Ltd. has a consensus price target of $7.99, signalling upside risk potential of 422.11%. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 13292.86%. Given that Aptorum Group Ltd. has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Aptorum Group Ltd. is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 APMAptorum Group Ltd.0 0 0 -
Is TLSA or APM More Risky?
Tiziana Life Sciences Ltd. has a beta of -0.047, which suggesting that the stock is 104.653% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.612%.
-
Which is a Better Dividend Stock TLSA or APM?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or APM?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Aptorum Group Ltd. quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than Aptorum Group Ltd.'s net income of --. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns TLSA or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of -373.3%. Tiziana Life Sciences Ltd.'s return on equity of -- beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About TLSA or AUTL?
Tiziana Life Sciences Ltd. has a consensus price target of $7.99, signalling upside risk potential of 422.11%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 480.62%. Given that Autolus Therapeutics Plc has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Autolus Therapeutics Plc is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is TLSA or AUTL More Risky?
Tiziana Life Sciences Ltd. has a beta of -0.047, which suggesting that the stock is 104.653% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock TLSA or AUTL?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or AUTL?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Tiziana Life Sciences Ltd.'s net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 8.72x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- AUTLAutolus Therapeutics Plc8.72x -- $21.1M -$78.6M
-
Which has Higher Returns TLSA or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About TLSA or BDRX?
Tiziana Life Sciences Ltd. has a consensus price target of $7.99, signalling upside risk potential of 422.11%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5406.23%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Biodexa Pharmaceuticals Plc is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is TLSA or BDRX More Risky?
Tiziana Life Sciences Ltd. has a beta of -0.047, which suggesting that the stock is 104.653% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock TLSA or BDRX?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or BDRX?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns TLSA or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of -2923.31%. Tiziana Life Sciences Ltd.'s return on equity of -- beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About TLSA or MREO?
Tiziana Life Sciences Ltd. has a consensus price target of $7.99, signalling upside risk potential of 422.11%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 213.11%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Mereo BioPharma Group Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 MREOMereo BioPharma Group Plc6 0 0 -
Is TLSA or MREO More Risky?
Tiziana Life Sciences Ltd. has a beta of -0.047, which suggesting that the stock is 104.653% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock TLSA or MREO?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or MREO?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 718.19x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- MREOMereo BioPharma Group Plc718.19x -- -- -$7M
-
Which has Higher Returns TLSA or NCNA?
NuCana Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About TLSA or NCNA?
Tiziana Life Sciences Ltd. has a consensus price target of $7.99, signalling upside risk potential of 422.11%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 622654.49%. Given that NuCana Plc has higher upside potential than Tiziana Life Sciences Ltd., analysts believe NuCana Plc is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 NCNANuCana Plc0 1 0 -
Is TLSA or NCNA More Risky?
Tiziana Life Sciences Ltd. has a beta of -0.047, which suggesting that the stock is 104.653% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock TLSA or NCNA?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or NCNA?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
